BsAb vs CAR-T design
| Class . | Agent . | Structure . | Target(s) . | Clones . |
|---|---|---|---|---|
| Bispecific antibody | Mosunetuzumab | IgG1 | CD3 × CD20 | Anti-CD3: UCHT1 (CD3ε) Anti-CD20: 2H7 (epitope shared w/rituximab) |
| Bispecific antibody | Epcoritamab | IgG1 | CD3 × CD20 | Anti-CD3: SP34-der (CD3ε) Anti-CD20: 7D8 (epitope shared w/ofatumumab) |
| Bispecific antibody | Odronextamab | IgG4 | CD3 × CD20 | Anti-CD3: REG1250 (CD3δε) Anti-CD20: 3B9-10 (epitope shared w/ofatumumab) |
| CAR T cell | Axicabtagene-ciloleucel | CD28 hinge CD28 transmembrane CD28 costimulatory CD3ζ signaling | CD19 | Anti-CD19: FMC63 (murine scFv) |
| CAR T cell | Tisagenlecleucel | CD8α hinge CD8α transmembrane 4-1BB costimulatory CD3ζ signaling | CD19 | Anti-CD19: FMC63 (murine scFv) |
| CAR T cell | Lisocabtagene-maraleucel | IgG4 hinge CD28 transmembrane 4-1BB costimulatory CD3ζ signaling | CD19 | Anti-CD19: FMC63 (murine scFv) |
| Class . | Agent . | Structure . | Target(s) . | Clones . |
|---|---|---|---|---|
| Bispecific antibody | Mosunetuzumab | IgG1 | CD3 × CD20 | Anti-CD3: UCHT1 (CD3ε) Anti-CD20: 2H7 (epitope shared w/rituximab) |
| Bispecific antibody | Epcoritamab | IgG1 | CD3 × CD20 | Anti-CD3: SP34-der (CD3ε) Anti-CD20: 7D8 (epitope shared w/ofatumumab) |
| Bispecific antibody | Odronextamab | IgG4 | CD3 × CD20 | Anti-CD3: REG1250 (CD3δε) Anti-CD20: 3B9-10 (epitope shared w/ofatumumab) |
| CAR T cell | Axicabtagene-ciloleucel | CD28 hinge CD28 transmembrane CD28 costimulatory CD3ζ signaling | CD19 | Anti-CD19: FMC63 (murine scFv) |
| CAR T cell | Tisagenlecleucel | CD8α hinge CD8α transmembrane 4-1BB costimulatory CD3ζ signaling | CD19 | Anti-CD19: FMC63 (murine scFv) |
| CAR T cell | Lisocabtagene-maraleucel | IgG4 hinge CD28 transmembrane 4-1BB costimulatory CD3ζ signaling | CD19 | Anti-CD19: FMC63 (murine scFv) |
scFv, single-chain variable fragments.